Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis

Results Demonstrate Robust Efficacy and Very Favorable Safety Profile

Viamet Pharmaceuticals, Inc. reported positive results from RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail. Onychomycosis is a chronic fungal infection involving the nail, nail bed, and surrounding tissues. VT-1161, the company’s lead product candidate, is a highly potent and selective orally available inhibitor of fungal CYP51.